Beyond the hematological targets CD19 and BCMA, the modularity of the CAR system allows for applications in solid tumors, infectious and autoimmune diseases, aging, and fibrosis, etc., by a simple substitution of domains (34–38). This evidence concerns the gene TNFRSF17 and autoimmune disease.